Beta blockers
for acute
Traumatic brain injury
SAMIR EL ANSARY
Global Critical Care
https://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY
Traumatic brain injury (TBI) is associated with
a systemic hyperadrenergic state.
Through activation of beta adrenoreceptors,
catecholamines may induce
hypermetabolism and increase both cardiac
and cerebral oxygen demands.
Common adverse effects of beta blockers were examined
including clinically significant hypotension, bradycardia,
bronchospasm and congestive heart failure.
The current body of
evidence is suggestive of a
benefit of beta blockers
following TBI.
Traumatic Brain Injury
A hyper-adrenergic state has long been
demonstrated in those patients with severe TBI,
as well as non-traumatic sub-arachnoid
hemorrhage.
This sympathetic hyperactivity may
present anywhere along the continuum; from a
mild and apparently benign SIRS state to
the disruptive and difficult to control
Paroxysmal sympathetic storms (PSS)
The most
severe form of the hyper-adrenergic states, PSS,
presents with paroxysmal sympathetic
system activation and adrenal release of
catecholamines.
These PSS events, with their
associated tachycardia, hypertension, tachypnea,
mydriasis, and diaphoresis, often
resemble those of pheochromocytoma and
Hyperthyroid storms
(Earning them the nickname
ā€œBrain stormsā€).
Several investigators have evaluated the post-TBI
state (with
regards to the plasma and urinary correlates of a
hyper-adrenergic phenomenon) and
noted a greater than 7-fold increase in
norepinephrine, epinephrine, and their urine
excreted metabolites.
Elevations appear to correlate with significant
increases in
sympathetic hyperactivity and are most
pronounced during the first week following
injury.
Neil-Dwyer and
colleagues published several studies on the hyper-
adrenergic state following intra-cranial
hemorrhage.
Although the majority of these related to patients
with nontraumatic SAH,
the group later published findings in the TBI
population as well.
The authors noted that in
both groups, patients with a clinically and/or
biochemically significant hyper-adrenergic
state appeared to have an increased morbidity and
mortality.
Mechanism involved
included a severe hyper-metabolic state,
myocardial ischemia/infarction, and pulmonary
dysfunction.
Other severely injured patients without TBI lacked
the catecholamine surge and
were noted to have better survival rates.
Administration of beta-blockers (BB) in patients
with severe TBI could
attenuate the hyper-adrenergic response, thereby
decreasing cardiac complications and
improving neurological recovery.
Mortality following
severe TBI has remained unacceptably high. Poor
outcomes are generally attributed to
the severity of the primary brain injury and little (if
any) real progress has been made on
improving survival.
Poor outcomes from severe TBI were not a
consequence of the primary insult that could not
be prevented, but rather a failure to utilize less
ā€œtraditionalā€ therapeutic approaches.
By
treating intra-cranial hypertension with a multi-
drug regimen, including scheduled
intravenous metoprolol and clonidine leading to
reduction in arterial inflow
pressure.
Through the use of this protocol, the Lund group
demonstrated a significant
reduction in mortality and improvement in
Glasgow Outcome Scale at six months
By investigating and treating the extra-cranial
manifestations (or non-neurological organ
dysfunction) of severe TBI, these previously
overlooked and harmful secondary insults
become potential avenues for improving survival in
this population.
We recently
demonstrated that exposure to beta-blockers in
patients with severe TBI was associated
with a significant reduction in mortality
This reduction in mortality is
even more impressive when considering
that the BB (+) group was older, more
severely
injured, had higher respiratory and
infectious complications, and had a
lower predicted
survival.
WHICH TBI PATIENTS GET BB?
All TBI patients with:
1) intra-cranial hemorrhage by CTH,
AND
2) persistent hyper-adrenergic state with
paroxysmal tachycardia, tachypnea and
hypertension; may also demonstrate diaphoresis,
mydriasis, agitation
WHICH BB TO USE AND HOW MUCH?
1. Propranolol and labetalol
are lipophilic, penetrate BBB, and exhibit
central &
peripheral actions.
2. Initiate propranolol @ 10 mg PT/PO
q8
3. If no gut access, use labetalol 10-20
mg I.V. q4
4. Utilize labetalol 10-40mg I.V. q2 prn
WHEN TO START AND HOW LONG TO
CONTINUE?
1. Initiate after 24-48 h, adequate
resuscitation.
2. Rule out sepsis, missed injuries, un-
addressed pain prior to initiating BB
3. Continue for at least 14 days.
May wean
as HR remains <100.
WHEN TO START AND HOW LONG TO
CONTINUE?
HOW TO TITRATE BB?
1. Consider titration to a mean HR< 90bpm
and/or improvement in symptom
severity/frequency
2. May also titrate for a return of CVRD to less
than 5%
Geriatric trauma
Numerous studies have documented the
beneficial effects of peri-operative beta
blockade
In patients undergoing non-cardiac surgery. In
addition to a significant reduction in
preoperative cardiac mortality, decreases in long-
term overall mortality, long-term
cardiac mortality, postoperative myocardial
infarction, and postoperative myocardial
ischemia have been demonstrated in patients
receiving beta-blockade in the peri-
operative period.
Geriatric trauma
The current ACC/AHA guidelines recommend
peri-operative beta
blockade as a Class I recommendation for
patients who required use of beta blockers in
the recent past for control of angina,
arrhythmia, or hypertension, and high-risk
patients with findings of ischemia on
preoperative testing undergoing vascular
surgery.
WHICH TRAUMA PATIENTS GET BB?
Use of beta-blockers in patients with (1)
prehospital use of BB, (2) known coronary artery
disease, or (3) age greater than 65 years
should be standard of care.
The College has placed this under the standards for
Patient Safety Practices along with DVT prophylaxis
and peri-operative antibiotics.
WHICH BB TO USE AND HOW
MUCH?
1. If patient is one home BB, this
medication should be restarted initially at ½
dose and
then titrated to full dose as tolerated.
2. If not on BB at home, but patient meets
indications, metoprolol should be utilized.
Start at 12.5-25 mg PO/PT q 12h. Titrate to
HR <80 bpm as BP tolerates.
WHICH BB TO USE AND HOW
MUCH?
3. If metoprolol proves ineffective,
propranolol can be utilized. Initiate @ 10
mg PT/PO q
8h.
4. If no gut access, use labetalol 10-20 mg
I.V. q 4h or metoprolol 5-10 mg I.V. q 4h
GOOD LUCK
SAMIR EL ANSARY
ICU PROFESSOR
AIN SHAMS
CAIRO
elansarysamir@yahoo.com
Global Critical Care
https://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY

More Related Content

PDF
Mannitol Vs Hypertonic Saline
PPTX
Beta blockers in Acute MI
PPTX
Traumatic brain injury: A brief review of treatment
PPTX
Hypertonic Saline Versus Mannitol for Increased Intracranial Pressure Management
PPTX
Beta blockers in STEMI
PPT
Beta blockers for heart failure
PPTX
Beta blocker in acute mi
PDF
Secondary Prevention after ACS - Role of Beta Blockers
Mannitol Vs Hypertonic Saline
Beta blockers in Acute MI
Traumatic brain injury: A brief review of treatment
Hypertonic Saline Versus Mannitol for Increased Intracranial Pressure Management
Beta blockers in STEMI
Beta blockers for heart failure
Beta blocker in acute mi
Secondary Prevention after ACS - Role of Beta Blockers

What's hot (20)

PPTX
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
PPTX
Beta blockers in cardiology
PPTX
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
PPT
Esmolol in Sepsis
Ā 
PPT
Influence B Blocker Mch Augustus 2008 1
PPTX
Heart Failure biomarkers
PDF
BCC4: Pierre Janin on Targets in Neuro-ICU
PPTX
Beta Blockers in current cardiovascular practice
PPTX
Role of anticoagulation in neurocritical care jhjk
PDF
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
PPT
Cardiovascular Biomarkers Lecture
PDF
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
PPT
Betablocker in chronic stable angina 24-01-2013.
PPT
Anticoagulation in cardio-embolic stroke : a debate
PPTX
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
PPTX
Biomarkers in heart failure
PPTX
Newer antiarrhythmics
PDF
Role of ACE Inhibitors as Secondary Prevention in ACS
PPTX
Treatment of Myocardial Infarction
PPTX
Antiplatelets in stroke recent scenario
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
Beta blockers in cardiology
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
Esmolol in Sepsis
Ā 
Influence B Blocker Mch Augustus 2008 1
Heart Failure biomarkers
BCC4: Pierre Janin on Targets in Neuro-ICU
Beta Blockers in current cardiovascular practice
Role of anticoagulation in neurocritical care jhjk
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
Cardiovascular Biomarkers Lecture
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
Betablocker in chronic stable angina 24-01-2013.
Anticoagulation in cardio-embolic stroke : a debate
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
Biomarkers in heart failure
Newer antiarrhythmics
Role of ACE Inhibitors as Secondary Prevention in ACS
Treatment of Myocardial Infarction
Antiplatelets in stroke recent scenario
Ad

Viewers also liked (18)

PPTX
Airway releasing ventilation
PPTX
Disseminated fungal infections 2015
PPTX
Sle pathophysiology and management
PPTX
New drugs and medical issues 2014 {2}
PPTX
Sle pathophysiology and management
PPTX
Ards management
PPTX
Chronic respiratory failure 1
PPTX
Colistin colistin (polymyxin e)
PPTX
Controlled ventilation 1
PPTX
Update in infectious diseases 1
PPTX
Airway releasing ventilation
PPTX
Brain ct and mri in icu
PPTX
Colistin colistin (polymyxin e)
PPTX
Conv. ventilation physi
PPT
Abg.2 Arterial blood gas analysis and example interpretation
PPTX
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
PPTX
Hyponatremia and hypernatremia 2015
PPTX
Community acquired pneumonia 2015
Airway releasing ventilation
Disseminated fungal infections 2015
Sle pathophysiology and management
New drugs and medical issues 2014 {2}
Sle pathophysiology and management
Ards management
Chronic respiratory failure 1
Colistin colistin (polymyxin e)
Controlled ventilation 1
Update in infectious diseases 1
Airway releasing ventilation
Brain ct and mri in icu
Colistin colistin (polymyxin e)
Conv. ventilation physi
Abg.2 Arterial blood gas analysis and example interpretation
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
Hyponatremia and hypernatremia 2015
Community acquired pneumonia 2015
Ad

Similar to Beta blockers in brain injuries (20)

PPTX
Beta blockers in brain injuries
PPT
Evidence Based Review CHF
PDF
Intracranial hemorrhage and intracranial hypertension
PPTX
Traumatic brain injury lecture g
PPT
TRAUMATIC BRAIN INJURY
PPTX
Questions and answers by Dr Maria graciela
PPTX
Traumatic brain injury lecture g
PPTX
From vertigo to coma basilar artery occlusion بالاتر Ų§Ų² Ų³ŪŒŲ§Ł‡ŪŒ Ų±Ł†ŚÆŪŒ Ł†ŪŒŲ³ŲŖ
PPTX
betablocker post MI clinical trial , for herat faliure with presered EF
PPT
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
PDF
Managing heart failure in eldery presentation
PPTX
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
PPT
Established uses of beta blockers
PPTX
HTN & CVA.pptx
PPTX
Beta blockers
PPT
Traumatic brain injury
PDF
Outpatient medicine, 2005
PPTX
Stroke hyperacute treatment
Ā 
PPTX
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
PPTX
Role of beta blocker and statin in primary prevention of cardiovascular disease
Beta blockers in brain injuries
Evidence Based Review CHF
Intracranial hemorrhage and intracranial hypertension
Traumatic brain injury lecture g
TRAUMATIC BRAIN INJURY
Questions and answers by Dr Maria graciela
Traumatic brain injury lecture g
From vertigo to coma basilar artery occlusion بالاتر Ų§Ų² Ų³ŪŒŲ§Ł‡ŪŒ Ų±Ł†ŚÆŪŒ Ł†ŪŒŲ³ŲŖ
betablocker post MI clinical trial , for herat faliure with presered EF
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
Managing heart failure in eldery presentation
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
Established uses of beta blockers
HTN & CVA.pptx
Beta blockers
Traumatic brain injury
Outpatient medicine, 2005
Stroke hyperacute treatment
Ā 
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
Role of beta blocker and statin in primary prevention of cardiovascular disease

More from samirelansary (20)

PPTX
Delerium in icu
PPTX
Cerebral monitoring
PPTX
Ventricular tachycardia
PPTX
Gaps in acid base balance in icu
PPTX
Chest x. ray interpretation and teaching
PPTX
Chest x. ray interpretation and teaching
PPTX
Cerebral monitoring
PPTX
Arterial line analysis
PPTX
X.ray pearls 1
PPTX
Subarachnoid haemorrhage
PPTX
Serotonin syndrome 2
PPTX
Principles of mechanical ventilation 2
PPTX
New critical care issues 2015 17
PPTX
Mixed connective tissue disease
PPTX
Intracranial pressure 2015
PPTX
Icu research points 2015 1
PPTX
Hyponatremia and hypernatremia 2015
PPTX
Hypokalemia
PPTX
Hyperkalemia
PPTX
Hepatitis and cirrhosis
Delerium in icu
Cerebral monitoring
Ventricular tachycardia
Gaps in acid base balance in icu
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
Cerebral monitoring
Arterial line analysis
X.ray pearls 1
Subarachnoid haemorrhage
Serotonin syndrome 2
Principles of mechanical ventilation 2
New critical care issues 2015 17
Mixed connective tissue disease
Intracranial pressure 2015
Icu research points 2015 1
Hyponatremia and hypernatremia 2015
Hypokalemia
Hyperkalemia
Hepatitis and cirrhosis

Recently uploaded (20)

PPTX
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
PDF
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
PPTX
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
PPT
Infections Member of Royal College of Physicians.ppt
PPTX
thio and propofol mechanism and uses.pptx
PDF
Forensic Psychology and Its Impact on the Legal System.pdf
PPTX
SHOCK- lectures on types of shock ,and complications w
PDF
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
PDF
The_EHRA_Book_of_Interventional Electrophysiology.pdf
PPT
nephrology MRCP - Member of Royal College of Physicians ppt
PPT
neurology Member of Royal College of Physicians (MRCP).ppt
PPTX
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
PPTX
ROJoson PEP Talk: What / Who is a General Surgeon in the Philippines?
PDF
Lecture 8- Cornea and Sclera .pdf 5tg year
PPTX
Vaccines and immunization including cold chain , Open vial policy.pptx
PPTX
@K. CLINICAL TRIAL(NEW DRUG DISCOVERY)- KIRTI BHALALA.pptx
PPTX
Approach to chest pain, SOB, palpitation and prolonged fever
PPT
Opthalmology presentation MRCP preparation.ppt
PDF
Nursing manual for conscious sedation.pdf
PPTX
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
Infections Member of Royal College of Physicians.ppt
thio and propofol mechanism and uses.pptx
Forensic Psychology and Its Impact on the Legal System.pdf
SHOCK- lectures on types of shock ,and complications w
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
The_EHRA_Book_of_Interventional Electrophysiology.pdf
nephrology MRCP - Member of Royal College of Physicians ppt
neurology Member of Royal College of Physicians (MRCP).ppt
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
ROJoson PEP Talk: What / Who is a General Surgeon in the Philippines?
Lecture 8- Cornea and Sclera .pdf 5tg year
Vaccines and immunization including cold chain , Open vial policy.pptx
@K. CLINICAL TRIAL(NEW DRUG DISCOVERY)- KIRTI BHALALA.pptx
Approach to chest pain, SOB, palpitation and prolonged fever
Opthalmology presentation MRCP preparation.ppt
Nursing manual for conscious sedation.pdf
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...

Beta blockers in brain injuries

  • 1. Beta blockers for acute Traumatic brain injury SAMIR EL ANSARY
  • 3. Traumatic brain injury (TBI) is associated with a systemic hyperadrenergic state. Through activation of beta adrenoreceptors, catecholamines may induce hypermetabolism and increase both cardiac and cerebral oxygen demands. Common adverse effects of beta blockers were examined including clinically significant hypotension, bradycardia, bronchospasm and congestive heart failure.
  • 4. The current body of evidence is suggestive of a benefit of beta blockers following TBI.
  • 5. Traumatic Brain Injury A hyper-adrenergic state has long been demonstrated in those patients with severe TBI, as well as non-traumatic sub-arachnoid hemorrhage. This sympathetic hyperactivity may present anywhere along the continuum; from a mild and apparently benign SIRS state to the disruptive and difficult to control Paroxysmal sympathetic storms (PSS)
  • 6. The most severe form of the hyper-adrenergic states, PSS, presents with paroxysmal sympathetic system activation and adrenal release of catecholamines. These PSS events, with their associated tachycardia, hypertension, tachypnea, mydriasis, and diaphoresis, often resemble those of pheochromocytoma and Hyperthyroid storms (Earning them the nickname ā€œBrain stormsā€).
  • 7. Several investigators have evaluated the post-TBI state (with regards to the plasma and urinary correlates of a hyper-adrenergic phenomenon) and noted a greater than 7-fold increase in norepinephrine, epinephrine, and their urine excreted metabolites. Elevations appear to correlate with significant increases in sympathetic hyperactivity and are most pronounced during the first week following injury.
  • 8. Neil-Dwyer and colleagues published several studies on the hyper- adrenergic state following intra-cranial hemorrhage. Although the majority of these related to patients with nontraumatic SAH, the group later published findings in the TBI population as well. The authors noted that in both groups, patients with a clinically and/or biochemically significant hyper-adrenergic state appeared to have an increased morbidity and mortality.
  • 9. Mechanism involved included a severe hyper-metabolic state, myocardial ischemia/infarction, and pulmonary dysfunction. Other severely injured patients without TBI lacked the catecholamine surge and were noted to have better survival rates. Administration of beta-blockers (BB) in patients with severe TBI could attenuate the hyper-adrenergic response, thereby decreasing cardiac complications and improving neurological recovery.
  • 10. Mortality following severe TBI has remained unacceptably high. Poor outcomes are generally attributed to the severity of the primary brain injury and little (if any) real progress has been made on improving survival. Poor outcomes from severe TBI were not a consequence of the primary insult that could not be prevented, but rather a failure to utilize less ā€œtraditionalā€ therapeutic approaches.
  • 11. By treating intra-cranial hypertension with a multi- drug regimen, including scheduled intravenous metoprolol and clonidine leading to reduction in arterial inflow pressure. Through the use of this protocol, the Lund group demonstrated a significant reduction in mortality and improvement in Glasgow Outcome Scale at six months
  • 12. By investigating and treating the extra-cranial manifestations (or non-neurological organ dysfunction) of severe TBI, these previously overlooked and harmful secondary insults become potential avenues for improving survival in this population. We recently demonstrated that exposure to beta-blockers in patients with severe TBI was associated with a significant reduction in mortality
  • 13. This reduction in mortality is even more impressive when considering that the BB (+) group was older, more severely injured, had higher respiratory and infectious complications, and had a lower predicted survival.
  • 14. WHICH TBI PATIENTS GET BB? All TBI patients with: 1) intra-cranial hemorrhage by CTH, AND 2) persistent hyper-adrenergic state with paroxysmal tachycardia, tachypnea and hypertension; may also demonstrate diaphoresis, mydriasis, agitation
  • 15. WHICH BB TO USE AND HOW MUCH? 1. Propranolol and labetalol are lipophilic, penetrate BBB, and exhibit central & peripheral actions. 2. Initiate propranolol @ 10 mg PT/PO q8 3. If no gut access, use labetalol 10-20 mg I.V. q4 4. Utilize labetalol 10-40mg I.V. q2 prn
  • 16. WHEN TO START AND HOW LONG TO CONTINUE? 1. Initiate after 24-48 h, adequate resuscitation. 2. Rule out sepsis, missed injuries, un- addressed pain prior to initiating BB 3. Continue for at least 14 days. May wean as HR remains <100.
  • 17. WHEN TO START AND HOW LONG TO CONTINUE? HOW TO TITRATE BB? 1. Consider titration to a mean HR< 90bpm and/or improvement in symptom severity/frequency 2. May also titrate for a return of CVRD to less than 5%
  • 18. Geriatric trauma Numerous studies have documented the beneficial effects of peri-operative beta blockade In patients undergoing non-cardiac surgery. In addition to a significant reduction in preoperative cardiac mortality, decreases in long- term overall mortality, long-term cardiac mortality, postoperative myocardial infarction, and postoperative myocardial ischemia have been demonstrated in patients receiving beta-blockade in the peri- operative period.
  • 19. Geriatric trauma The current ACC/AHA guidelines recommend peri-operative beta blockade as a Class I recommendation for patients who required use of beta blockers in the recent past for control of angina, arrhythmia, or hypertension, and high-risk patients with findings of ischemia on preoperative testing undergoing vascular surgery.
  • 20. WHICH TRAUMA PATIENTS GET BB? Use of beta-blockers in patients with (1) prehospital use of BB, (2) known coronary artery disease, or (3) age greater than 65 years should be standard of care. The College has placed this under the standards for Patient Safety Practices along with DVT prophylaxis and peri-operative antibiotics.
  • 21. WHICH BB TO USE AND HOW MUCH? 1. If patient is one home BB, this medication should be restarted initially at ½ dose and then titrated to full dose as tolerated. 2. If not on BB at home, but patient meets indications, metoprolol should be utilized. Start at 12.5-25 mg PO/PT q 12h. Titrate to HR <80 bpm as BP tolerates.
  • 22. WHICH BB TO USE AND HOW MUCH? 3. If metoprolol proves ineffective, propranolol can be utilized. Initiate @ 10 mg PT/PO q 8h. 4. If no gut access, use labetalol 10-20 mg I.V. q 4h or metoprolol 5-10 mg I.V. q 4h
  • 23. GOOD LUCK SAMIR EL ANSARY ICU PROFESSOR AIN SHAMS CAIRO elansarysamir@yahoo.com Global Critical Care https://www.facebook.com/groups/1451610115129555/#!/groups/145 1610115129555/ Wellcome in our new group ..... Dr.SAMIR EL ANSARY